Boston Scientific Corporation (0HOY.L)
USD 102.19
(0.98%)
USD 102.19
(0.98%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 7.5 Billion USD | 27.44% |
| 2022 | 5.89 Billion USD | 6.34% |
| 2021 | 5.53 Billion USD | 11.34% |
| 2020 | 4.97 Billion USD | -3.72% |
| 2019 | 5.16 Billion USD | 9.01% |
| 2018 | 4.74 Billion USD | 9.07% |
| 2017 | 4.34 Billion USD | 5.82% |
| 2016 | 4.1 Billion USD | -27.59% |
| 2015 | 5.67 Billion USD | 5.23% |
| 2014 | 5.39 Billion USD | 13.86% |
| 2013 | 4.73 Billion USD | -44.99% |
| 2012 | 8.6 Billion USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 1.74 Billion USD | -0.8% |
| 2024 Q2 | 2.32 Billion USD | 33.39% |
| 2024 Q3 | 2.17 Billion USD | -14.95% |
| 2023 Q3 | 1.6 Billion USD | -6.72% |
| 2023 Q4 | 1.75 Billion USD | 9.01% |
| 2023 Q1 | 1.56 Billion USD | 3.72% |
| 2023 Q2 | 1.72 Billion USD | 10.44% |
| 2023 FY | 6.65 Billion USD | 12.9% |
| 2022 Q4 | 1.5 Billion USD | 2.59% |
| 2022 Q2 | 1.51 Billion USD | 9.02% |
| 2022 Q1 | 1.38 Billion USD | -6.6% |
| 2022 FY | 5.89 Billion USD | 6.34% |
| 2022 Q3 | 1.46 Billion USD | -2.85% |
| 2021 Q3 | 1.39 Billion USD | -2.87% |
| 2021 FY | 5.53 Billion USD | 11.34% |
| 2021 Q1 | 1.44 Billion USD | -14.49% |
| 2021 Q2 | 1.43 Billion USD | -0.63% |
| 2021 Q4 | 1.48 Billion USD | 6.76% |
| 2020 Q3 | 1.92 Billion USD | 48.49% |
| 2020 Q4 | 1.68 Billion USD | -12.29% |
| 2020 FY | 4.97 Billion USD | -3.72% |
| 2020 Q1 | 1.61 Billion USD | -16.84% |
| 2020 Q2 | 1.29 Billion USD | -19.94% |
| 2019 Q3 | 1.73 Billion USD | 6.17% |
| 2019 Q2 | 1.63 Billion USD | 37.71% |
| 2019 FY | 5.16 Billion USD | 9.01% |
| 2019 Q1 | 1.18 Billion USD | -21.22% |
| 2019 Q4 | 1.94 Billion USD | 11.8% |
| 2018 Q3 | 1.19 Billion USD | -10.66% |
| 2018 Q1 | 1.3 Billion USD | -10.25% |
| 2018 Q2 | 1.33 Billion USD | 2.07% |
| 2018 Q4 | 1.5 Billion USD | 26.72% |
| 2018 FY | 4.74 Billion USD | 9.07% |
| 2017 Q1 | 1.14 Billion USD | -20.61% |
| 2017 FY | 4.34 Billion USD | 5.82% |
| 2017 Q4 | 1.45 Billion USD | 19.47% |
| 2017 Q3 | 1.21 Billion USD | -17.27% |
| 2017 Q2 | 1.47 Billion USD | 28.58% |
| 2016 FY | 4.1 Billion USD | -27.59% |
| 2016 Q1 | 1.09 Billion USD | -36.34% |
| 2016 Q2 | 1.81 Billion USD | 65.87% |
| 2016 Q3 | 1.18 Billion USD | -34.69% |
| 2016 Q4 | 1.44 Billion USD | 21.71% |
| 2015 Q4 | 1.71 Billion USD | 4.25% |
| 2015 Q3 | 1.64 Billion USD | 52.22% |
| 2015 FY | 5.67 Billion USD | 5.23% |
| 2015 Q2 | 1.08 Billion USD | -12.03% |
| 2015 Q1 | 1.23 Billion USD | -32.49% |
| 2014 FY | 5.39 Billion USD | 13.86% |
| 2014 Q2 | 1.34 Billion USD | 34.1% |
| 2014 Q4 | 1.82 Billion USD | 48.37% |
| 2014 Q3 | 1.22 Billion USD | -8.43% |
| 2014 Q1 | 1 Billion USD | -12.36% |
| 2013 Q1 | 1.47 Billion USD | 34.03% |
| 2013 Q3 | 1.1 Billion USD | 8.15% |
| 2013 Q4 | 1.14 Billion USD | 3.63% |
| 2013 FY | 4.73 Billion USD | -44.99% |
| 2013 Q2 | 1.01 Billion USD | -30.89% |
| 2012 Q4 | 1.09 Billion USD | 0.0% |
| 2012 FY | 8.6 Billion USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Phreesia, Inc. | 369.84 Million USD | -1929.521% |
| Accuray Incorporated | 142.61 Million USD | -5163.047% |
| Align Technology, Inc. | 2.07 Billion USD | -261.417% |
| Elevance Health Inc. | 36.23 Billion USD | 79.286% |
| AxoGen, Inc. | 149.33 Million USD | -4926.25% |
| CVS Health Corporation | 40.68 Billion USD | 81.552% |
| Cardinal Health, Inc. | 5 Billion USD | -50.12% |
| Centene Corporation | 138.33 Billion USD | 94.574% |
| DaVita Inc. | 1.47 Billion USD | -409.232% |
| HCA Healthcare, Inc. | 45.43 Billion USD | 83.481% |
| Hologic, Inc. | 1.26 Billion USD | -492.143% |
| Humana Inc. | 102.36 Billion USD | 92.667% |
| IDEXX Laboratories, Inc. | 1.09 Billion USD | -586.833% |
| Laboratory Corporation of America Holdings | 2.02 Billion USD | -271.327% |
| Masimo Corporation | 867 Million USD | -765.744% |
| McKesson Corporation | 8.67 Billion USD | 13.476% |
| Patterson Companies, Inc. | 1.12 Billion USD | -565.828% |
| Quest Diagnostics Incorporated | 1.61 Billion USD | -366.211% |
| ResMed Inc. | 1.36 Billion USD | -448.535% |
| Henry Schein, Inc. | 2.93 Billion USD | -155.567% |
| Teladoc Health, Inc. | 2.09 Billion USD | -258.978% |
| Universal Health Services, Inc. | 9.2 Billion USD | 18.487% |
| Veeva Systems Inc. | 1.25 Billion USD | -497.113% |
| Baxter International Inc. | 5.27 Billion USD | -42.375% |
| Becton, Dickinson and Company | 6.71 Billion USD | -11.83% |
| Intuitive Surgical, Inc. | 2.96 Billion USD | -153.35% |
| Danaher Corporation | 8.75 Billion USD | 14.266% |
| Stryker Corporation | 9.2 Billion USD | 18.493% |
| Medtronic plc | 16.12 Billion USD | 53.463% |